Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
terminated

Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders

key information

study id #: NCT00839033

condition: Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis, Neuromuscular Diseases

status: terminated

purpose:

The hypothesis is that a mechanical insufflation-exsufflation (MI-E) is associated with a decrease in the number of intubations and more rapid clinical improvement in children and adults with neuromuscular disease who are admitted for an acute respiratory exacerbation.In this prospective, randomised, multicenter study, 55 patients will be treated with standard treatment and a MI-E, and 55 patients with standard treatment and standard respiratory physiotherapy. The primary objective is the reduction of the number of patients requiring invasive ventilatory support (endotracheal intubation or tracheotomy) in the group treated with MI-E (MI-E group). The main secondary objectives are a reduction in hospital stay and an improvement in clinical condition, dyspnea and respiratory muscle function.

intervention: mechanical insufflation - exsufflation, Standard respiratory physiotherapy

mechanism of action: No pharmaceutical intervention

results: https://clinicaltrials.gov/ct2/show/results/NCT00839033

last updated: November 22, 2018

study details

start date: June 2009

estimated completion: February 2011

phase of development: Phase 3

size / enrollment: 14

study description:
Justification Respiratory muscle weakness reduces the efficacy of the cough reflex in patients with neuromuscular disorders and exposes them to the risk of acute respiratory failure. Mechanical insufflation-exsufflation devices assist cough and have been shown to be efficient in increasing the cough expiratory flow in children and adults with neuromuscular disease and decreasing the risk of intubation in a limited population of hospitalized adults with acute respiratory failure.
Primary objective: The goal is to record the efficacy of mechanical insufflation-exsufflation (MI-E) during acute respiratory failure in patients with neuromuscular disorders. The primary objective is the reduction of the number of patients requiring invasive ventilatory support (endotracheal intubation or tracheotomy) in the group treated with MI-E (MI-E group) compared to the group treated with traditional chest physiotherapy without MI-E (Control group).
Secondary objectives: In the MI-E group, compared to the Control group:
• Decrease in the length of hospitalization in the intensive care unit (ICU)
• Decrease in the total length of hospitalization
• Decrease in the incidence of bronchoscopy-assisted aspiration
• Decrease in the duration of oxygen therapy
• Decrease in the daily length of noninvasive positive pressure ventilation (NPPV)
• Improvement in blood gases on room air during hospitalization
• Improvement of the peak cough flow (PCF)
• Improvement of the vital capacity (VC), maximal inspiratory (PImax) and expiratory (PEmax) pressures, sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF) and dyspnea during hospitalization
• Decrease in the number of secondary tracheotomies (for weaning of ventilatory support)
Type of study: Prospective, randomized, controlled, multicenter study
Number of subjects:
(1). The calculation of the number of subjects is based on two retrospective studies. In the study by VIANELLO, which included 11 adults hospitalized in the ICU for respiratory failure, the number of therapeutic failures, defined as the need for a "mini" tracheotomy or intubation, was significantly less in the group using MI-E than in a group of 16 historical control patients [2 failures in the MI-E group (18%) versus 10 failures in the control group (63%), p<0.05].
(2). Another study reported 19 successes (80%) versus 5 failures on MI-E.

primary outcomes:

  • Reduction of the number of patients requiring invasive ventilatory support in the group treated with MI-E (MI-E group) compared to the group treated with traditional chest physiotherapy without MI-E (Control group). [Time Frame: During the treatment phase]

secondary outcomes:

  • Decrease in the length of hospitalization in the intensive care unit (ICU) (if necessary) [Time Frame: During the treatment phase]
  • Decrease in the total length of hospitalization [Time Frame: During the treatment phase]
  • Decrease in the incidence of bronchoscopy-assisted aspiration [Time Frame: During the treatment phase ]
  • Decrease in the duration of oxygen therapy [Time Frame: During the treatment phase]
  • Decrease in the daily length of noninvasive positive pressure ventilation (NPPV) [Time Frame: During the treatment phase]
  • Improvement in blood gases on room air during hospitalization and improvement of the peak cough flow (PCF) [Time Frame: During the treatment phase]
  • Improvement of the vital capacity (VC), maximal inspiratory (PImax) and expiratory (PEmax) pressures, sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF) and dyspnea during hospitalization [ Time Frame: During the treatment phase]
  • Decrease in the number of secondary tracheotomies (for weaning of ventilatory support) [Time Frame: During the treatment phase]

inclusion criteria:
Pediatric or adult patients with chronic neuromuscular disorders, such as spinal muscular atrophy, Duchenne muscular dystrophy, other congenital myopathy, or amyotrophic lateral sclerosis (ALS), hospitalized for acute respiratory failure, as defined by:
• Persistent bronchial encumbrance (> 2 days) despite regular treatment in the homecare setting, associated with-Oxygen desaturation on room air, defined by a pulse oximetry (SaO2) <95%) or
• In patients not receiving long-term NPPV: the need to institute NPPV-In patients receiving long-term NPPV: the need to increase the daily length of NPPV by at least 25%.

exclusion criteria:
• Need for immediate intubation (alteration in consciousness, coma, hemodynamic disorders)
• Multiple organ failure (e.g., associated cardiac failure)
• In adults: respiratory rate >30/min, pH < 7.35, PaCO2 > 50 mm Hg
• Facial deformity or anomaly which prevents the use of a mouthpiece or mask
• Patients who signed a refusal to be intubated regardless of the progression of their disease
• Patients on long-term oxygen therapy
• Tracheotomized patients
• Patients requiring the use of an intrapulmonary percussive ventilation device during hospitalization
• Acute neuromuscular disorder of known or unknown etiology
• Associated lung disease such as chronic obstructive pulmonary disease (COPD)
• Refusal of patient consent and/or parental consent in the case of a minor
• Uncooperative patients
• Patients < 4 years old

study contacts

sponsor: Assistance Publique - Hôpitaux de Paris

investigators: Brigitte FAUROUX, MD PhD

locations: France